| Code | CSB-RA619082MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to FB-1001, targeting NTRK2 (TrkB), a receptor tyrosine kinase that plays a critical role in neuronal development, synaptic plasticity, and neuronal survival. NTRK2 binds brain-derived neurotrophic factor (BDNF) and other neurotrophins, initiating signaling cascades essential for nervous system function and maintenance. Aberrant NTRK2 expression and activation have been implicated in various neurological disorders, neurodegenerative diseases, and certain cancers, where NTRK2 gene fusions can drive oncogenic transformation. Additionally, altered NTRK2 signaling is associated with mood disorders, cognitive impairment, and pain pathways.
FB-1001 was developed as a therapeutic antibody candidate targeting NTRK2, with potential applications in oncology and neurological conditions. This biosimilar provides researchers with a valuable tool for investigating NTRK2-mediated signaling pathways, studying receptor-ligand interactions, and exploring the role of tropomyosin receptor kinases in disease pathogenesis. It supports diverse research applications in neuroscience, cancer biology, and drug discovery programs focused on NTRK-related therapeutics.
There are currently no reviews for this product.